Canada reports 1st blood clot in AstraZeneca COVID-19 vaccine recipient

0
212

Canada announced on Tuesday its first report of a rare blood clot in a person who had received the AstraZeneca COVID-19 vaccine.

The Public Health Agency of Canada (PHAC) said in a statement the person is at home recovering.

Read more:
‘Possible’ link between AstraZeneca vaccine and rare blood clots, EU drug regulator says

“Reports of blood clots with low platelets in people vaccinated with the AstraZeneca COVID-19 vaccine are very rare and the report of this case shows that Canada’s vaccine safety monitoring system works,” PHAC said in a statement.

The vaccine was produced at the Serum Institute of India, known as Covishield.

In March, Canadian health regulators said AstraZeneca’s COVID-19 vaccine cannot be administered to people under the age of 55 due to concerns over reports of rare blood clots.

Story continues below advertisement

“Based on all of the evidence available internationally to-date, Health Canada continues to consider that the benefits of the AstraZeneca and COVISHIELD vaccines to protect against COVID-19 outweigh the potential risks,” the statement read.


Click to play video: 'Canada advised to pause AstraZeneca COVID-19 shots for those under 55'



3:17
Canada advised to pause AstraZeneca COVID-19 shots for those under 55


Canada advised to pause AstraZeneca COVID-19 shots for those under 55 – Mar 29, 2021

More to come

© 2021 Global News, a division of Corus Entertainment Inc.